A Study of Tamiflu (Oseltamivir) Treatment in Laboratory-Confirmed Influenza.
|ClinicalTrials.gov Identifier: NCT00436124|
Recruitment Status : Terminated (poor recruitment, no patients were enrolled)
First Posted : February 16, 2007
Last Update Posted : February 17, 2017
|Condition or disease||Intervention/treatment||Phase|
|Influenza||Drug: oseltamivir [Tamiflu]||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized, Open Label Study to Evaluate the Effect of Tamiflu on Viral Shedding and on Serum and Cytoplasmic Inflammatory Cytokine Concentrations in Patients With Laboratory-confirmed Influenza|
|Actual Study Start Date :||January 2007|
|Primary Completion Date :||April 2007|
|Study Completion Date :||April 2007|
- Viral shedding; serum and intracellular concentrations of inflammatory cytokines (INFgamma, TNFalpha, IL-6, IL-12).
- Efficacy: Duration of illness, health and functional status, extent and severity of symptoms, incidence of resistant viruses. Safety: AEs.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00436124
|Study Director:||Clinical Trials||Hoffmann-La Roche|